Adial receives $1.425 million in net proceeds from exercise of warrants

Charlottesville, va., feb. 26, 2021 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced the exercise of 712,500 warrants from its june 2020 financing for net proceeds to the company of $1,425,000.
ADIL Ratings Summary
ADIL Quant Ranking